https://nova.newcastle.edu.au/vital/access/ /manager/Index ${session.getAttribute("locale")} 5 FDG-PET parameters predict for recurrence in anal cancer - results from a prospective, multicentre clinical trial https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:45220 Wed 26 Oct 2022 19:56:49 AEDT ]]> Prostate external beam radiotherapy combined with high-dose-rate brachytherapy: dose-volume parameters from deformably-registered plans correlate with late gastrointestinal complications https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:29346 Wed 23 Feb 2022 16:04:41 AEDT ]]> Impact of treatment planning and delivery factors on gastrointestinal toxicity: an analysis of data from the RADAR prostate radiotherapy trial https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:16753 Wed 11 Apr 2018 15:29:36 AEST ]]> Registering prostate external beam radiotherapy with a boost from high-dose-rate brachytherapy: a comparative evaluation of deformable registration algorithms https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:25925 Wed 11 Apr 2018 14:57:01 AEST ]]> A prospective study of nomogram-based adaptation of prostate radiotherapy target volumes https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:24716 Wed 11 Apr 2018 14:27:57 AEST ]]> Infections after fiducial marker implantation for prostate radiotherapy: are we underestimating the risks? https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:27681 Wed 11 Apr 2018 13:22:02 AEST ]]> Phase I trial of hypofractionated chemoradiotherapy in the palliative management of esophageal and gastro-esophageal cancer https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:51990 Tue 26 Sep 2023 10:53:57 AEST ]]> Validation of an MRI-only planning workflow for definitive pelvic radiotherapy https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:48126 99% for criteria of 3%/2 mm and 2%/2 mm. With dose criteria of 1%/1 mm, the pass rate was higher for the male cohort at 96.3% than the female cohort at 93.4%. MRI to sCT anatomical agreement for bone and body delineated contours was assessed, with a resulting Dice score of 0.91 ± 0.2 (mean ± 1 SD) and 0.97 ± 0.0 for the male cohort respectively; and 0.96 ± 0.0 and 0.98 ± 0.0 for the female cohort respectively. The mean absolute error in Hounsfield units (HUs) within the entire body for the male and female cohorts was 59.1 HU ± 7.2 HU and 53.3 HU ± 8.9 HU respectively. Conclusions: A multi-atlas based method for sCT generation can be applied to a standard T1-weighted MRI sequence for male and female pelvic patients. The implications of this study support MRI only planning being applied more broadly for both male and female pelvic sites.]]> Tue 21 Mar 2023 15:07:30 AEDT ]]> A remote EPID-based dosimetric TPS-planned audit of centers for clinical trials: outcomes and analysis of contributing factors https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:42881 1 for four comparisons, indicating higher GPRs of the remote audit than the reference audits. Conclusion: The remote dosimetry audit method for clinical trials demonstrated high GPRs and provided results comparable to established more resource-intensive audit methods. Several factors were found to influence the results including some effect of Linac-TPS combination.]]> Tue 06 Sep 2022 11:51:21 AEST ]]> Investigation of a real-time EPID-based patient dose monitoring safety system using site-specific control limits https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:29628 Thu 27 Jan 2022 15:55:44 AEDT ]]> The impact of contour variation on tumour control probability in anal cancer https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:32548 Thu 24 Mar 2022 11:30:42 AEDT ]]> Real-time in vivo rectal wall dosimetry using MOSkin detectors during linac based stereotactic radiotherapy with rectal displacement https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:43577 Skin detectors were an effective tool for measuring dose delivered to the anterior rectal wall in real time during prostate SBRT boost treatments for the purpose of both ensuring the rectal doses remain within acceptable limits during the treatment and for the verification of final rectal doses.]]> Mon 26 Sep 2022 10:27:37 AEST ]]> Quality assurance analysis of hippocampal avoidance in a melanoma whole brain radiotherapy randomized trial shows good compliance https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:41259 Mon 01 Aug 2022 09:21:45 AEST ]]>